{"id":2722,"date":"2019-02-18T13:09:25","date_gmt":"2019-02-18T12:09:25","guid":{"rendered":"http:\/\/www.irlab.se\/?page_id=2722"},"modified":"2022-03-10T11:45:19","modified_gmt":"2022-03-10T10:45:19","slug":"initial-public-offering","status":"publish","type":"page","link":"https:\/\/irlab.se\/sv\/initial-public-offering\/","title":{"rendered":"B\u00f6rsnotering 2017"},"content":{"rendered":"\n

IRLAB Therapeutics AB (publ) avser att lista sina aktier p\u00e5 Nasdaq First North Premier<\/h2>\n\n\n\n

IRLAB Therapeutics AB (publ) (\u201dIRLAB\u201d) \u00e4r verksamt inom forskning och utveckling av l\u00e4kemedel mot sjukdomar i hj\u00e4rnan, med fokus p\u00e5 Parkinsons sjukdom. Initialt ligger fokus p\u00e5 l\u00e4kemedelskandidaten IRL752 som \u00e4r inriktad p\u00e5 demens vid Parkinsons sjukdom och IRL790 som \u00e4r inriktad p\u00e5 LIDs (levodopa-inducerade dyskinesier) och psykos vid Parkinsons sjukdom.<\/p>\n\n\n\n

Pressmeddelanden<\/h3>\n\n\n\n

2017-02-14 IRLAB Therapeutics offentligg\u00f6r utfall i nyemission \u2013 f\u00f6rsta handelsdag planerad till 28 februari<\/a><\/p>\n\n\n\n

2017-02-10 IRLAB Therapeutics har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq First North Premier<\/a><\/p>\n\n\n\n

2017-01-30 IRLAB Therapeutics inleder teckningsperiod f\u00f6r nyemission inf\u00f6r listning p\u00e5 Nasdaq First North Premier<\/a><\/p>\n\n\n\n

2017-01-25 IRLAB Therapeutics ans\u00f6ker om listning p\u00e5 Nasdaq First North Premier och offentligg\u00f6r prospekt<\/a><\/p>\n\n\n\n

\n\n\n\n\t\n\n\t\n\t\n\t
Erbjudandet i korthet<\/th>\n<\/tr>\n<\/thead>\n
Pris per aktie<\/td>60 SEK<\/td>\n<\/tr>\n
Anm\u00e4lningsperiod f\u00f6r teckning av aktier i Erbjudandet\u00a0<\/td>11-21 februari<\/td>\n<\/tr>\n
Prelimin\u00e4r f\u00f6rsta handelsdag<\/td>28 februari<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/h3>\n\n\n\n
<\/div>\n\n\n\n

Dokument<\/h3>\n\n\n\n

Prospekt<\/a><\/p>\n\n\n\n

Anm\u00e4lningssedel<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

IRLAB Therapeutics AB (publ) avser att lista sina aktier p\u00e5 Nasdaq First North Premier IRLAB Therapeutics AB (publ) (\u201dIRLAB\u201d) \u00e4r verksamt inom forskning och utveckling av l\u00e4kemedel mot sjukdomar i hj\u00e4rnan, med fokus p\u00e5 Parkinsons sjukdom. Initialt ligger fokus p\u00e5 l\u00e4kemedelskandidaten IRL752 som \u00e4r inriktad p\u00e5 demens vid Parkinsons sjukdom och IRL790 som \u00e4r inriktad […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page__disclaimer.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2722","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nB\u00f6rsnotering 2017 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/initial-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"B\u00f6rsnotering 2017 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB Therapeutics AB (publ) avser att lista sina aktier p\u00e5 Nasdaq First North Premier IRLAB Therapeutics AB (publ) (\u201dIRLAB\u201d) \u00e4r verksamt inom forskning och utveckling av l\u00e4kemedel mot sjukdomar i hj\u00e4rnan, med fokus p\u00e5 Parkinsons sjukdom. Initialt ligger fokus p\u00e5 l\u00e4kemedelskandidaten IRL752 som \u00e4r inriktad p\u00e5 demens vid Parkinsons sjukdom och IRL790 som \u00e4r inriktad […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/initial-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-10T10:45:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/initial-public-offering\/\",\"url\":\"https:\/\/irlab.se\/sv\/initial-public-offering\/\",\"name\":\"B\u00f6rsnotering 2017 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2019-02-18T12:09:25+00:00\",\"dateModified\":\"2022-03-10T10:45:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/initial-public-offering\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/initial-public-offering\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/initial-public-offering\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"B\u00f6rsnotering 2017\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"B\u00f6rsnotering 2017 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/initial-public-offering\/","og_locale":"sv_SE","og_type":"article","og_title":"B\u00f6rsnotering 2017 - IRLAB","og_description":"IRLAB Therapeutics AB (publ) avser att lista sina aktier p\u00e5 Nasdaq First North Premier IRLAB Therapeutics AB (publ) (\u201dIRLAB\u201d) \u00e4r verksamt inom forskning och utveckling av l\u00e4kemedel mot sjukdomar i hj\u00e4rnan, med fokus p\u00e5 Parkinsons sjukdom. Initialt ligger fokus p\u00e5 l\u00e4kemedelskandidaten IRL752 som \u00e4r inriktad p\u00e5 demens vid Parkinsons sjukdom och IRL790 som \u00e4r inriktad […]","og_url":"https:\/\/irlab.se\/sv\/initial-public-offering\/","og_site_name":"IRLAB","article_modified_time":"2022-03-10T10:45:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/initial-public-offering\/","url":"https:\/\/irlab.se\/sv\/initial-public-offering\/","name":"B\u00f6rsnotering 2017 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2019-02-18T12:09:25+00:00","dateModified":"2022-03-10T10:45:19+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/initial-public-offering\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/initial-public-offering\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/initial-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"B\u00f6rsnotering 2017"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/2722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=2722"}],"version-history":[{"count":13,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/2722\/revisions"}],"predecessor-version":[{"id":8796,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/2722\/revisions\/8796"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=2722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}